EMEA-001178-PIP01-11-M06
Key facts
| Invented name |
Stivarga
|
| Active substance |
regorafenib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0495/2021
|
| PIP number |
EMEA-001178-PIP01-11-M06
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bayer AG
E-mail: pediatrics.medical-affairs-europe@bayer.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|